Details
Category: Volume 08 Issue 10 October 2020
Hits: 932

Title: Correlation of Serum Uric Acid Level and Microvascular Complications in Patients with Type 2 Diabetes Mellitus

Authors: Dr Akita Gopinath, Dr K. Suresh, Dr P. Muraliswaran

 DOI: https://dx.doi.org/10.18535/jmscr/v8i10.39

Abstract

Diabetes mellitus has become a significant health challenge overall. It is a chronic, heterogeneous metabolic disorder that manifests as hyperglycemia and is characterized by impaired insulin secretion, insulin resistance, and increased hepatic glucose production. Microvascular dysfunction is unique to diabetes and characterized by nonocclusive microcirculatory disease. Hyperuricemia has been found to be associated insulin resistance, and consequently with type 2 diabetes. Potentially important biological effects of uric acid relate to endothelial dysfunction by inducing antiproliferative effects on endothelium and impairing nitric oxide production and inflammation. Here an attempt has been made to study the level of serum uric acid in Type 2 diabetes mellitus and correlating it with development of microvascular complications.

Keywords: Serum Uric Acid, Type 2 Diabetes Mellitus.

References

  1. Xiong Q, Liu J, Xu Y. Effects of uric acid on diabetes mellitus and its chronic complications. International Journal of Endocrinology. 2019 Oct 13;2019.
  2. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:1327–1334, 2009.
  3. American Diabetes Association: Standards of medical care in diabetes–2014. Diabetes Care 37 (Suppl 1):S14–S80, 2014.
  4. The World Health Organization, International Diabetes Federation: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultatIon. Geneva, Switzerland, 2006, World Health Organization.
  5. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 13:1–11, 1990.
  6. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 11:309–317, 1993.
  7. Stratton IM, Adler AI, Neil HA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412, 2000.
  8. Seshasai SR, Kaptoge S, Thompson A, et al: Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med 364:829–841, 2011.
  9. Loe H: Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care 16:329–334, 1993.
  10. Babu AR, Herdegen J, Fogelfeld L, et al: Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 165:447–452, 2005.
  11. Jeon CY, Murray MB: Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 5:e152, 2008.
  12. Rubin RR, Peyrot M: Quality of life and diabetes. Diabetes Metab Res Rev 15:205–218, 1999.
  13. Narayan KM, Boyle JP, Thompson TJ, et al: Lifetime risk for diabetes mellitus in the United States. JAMA 290:1884–1890, 2003.
  14. National diabetes audit 2010–2011 report 2: complications and mortality. September 28, 2012, at https://catalogue.ic.nhs.uk/publications/clinical/diabetes/nati-diab-audi-10 11/nati-diab-aud- 10-11-comp-and-mort-v2.pdf. Accessed in 2020.
  15. Centers for Disease Control and Prevention: National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011, Atlanta, GA, 2011, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
  16. Boles M, Pelletier B, Lynch W: The relationship between health risks and work productivity. J Occup Environ Med 46:737–745, 2004.
  17. American Diabetes Association: Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36:1033–1046, 2013.
  18. Kumpatla S, Kothandan H, Tharkar S, et al: The costs of treating long term diabetic complications in a developing country: a study from India. J Assoc Phys India 61:16–23, 2013.
  19. Gaede P, Lund-Andersen H, Parving HH, et al: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591, 2008.
  20. Gaede P, Vedel P, Larsen N, et al: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393, 2003.
  21. Saaddine JB, Cadwell B, Gregg EW, et al: Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med 144:465–474, 2006.
  22. Performance measurement set for adult diabetes. January 21, 2005. Accessed in 2020, at www.nyqa.org/pdf-lib/NDQIA%20Diabetes%20DomainFinal2005Measures.pdf.
  23. Chan JC, Gagliardino JJ, Baik SH, et al: Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 32:227–233,2009.
  24. Lozano R, Naghavi M, Foreman K, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:2095–2128, 2012.

Corresponding Author

Dr Akita Gopinath

Dept. of General Medicine, Sri Venkateshwaraa Medical College Hospital & Research Centre, Ariyur, Puducherry 605102, India